Atlas Trials

A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])

Clinical trial NCT04835714 · TERMINATED

Trial details

NCT number
NCT04835714
Sponsor
Boehringer Ingelheim
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Solid Tumors, KRAS Mutation
Start date
2021-04-20
Primary completion
2022-01-18
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.